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Background: Colorectal carcinoma (CRC) is the seventh-most common malignancy and is the main cause of
death in Iraq. The incidence of this cancer has increased sharply after the invasion of Iraq in 2003.
Aim: To estimate immunohistochemical expression of vascular endothelial growth factor (VEGF)i nC R Ci n
relation to other parameters, such as grade and stage of tumour.
Methods: Formalin fixed, paraffin-embedded blocks from 52 patients (27 male and 25 female) with CRC were
included in this study. A group of 22 patients with non-cancerous colonic tissues were included as a control
group. Avidinbiotin complex method was employed for immunohistochemical detection of VEGF.
Results: VEGF immuno-expression was positive in 51.9% of CRC, while it was 18.2% in the normal colonic
tissue (pB0.05). VEGF immunostaining was positively correlatedwith grade of colonic malignancy (pB0.05).
Conclusion: These findings provide further evidence for the role of VEGF in the carcinogenesis of CRC.
However, VEGF could not be well correlated with stage of tumour and hence may be a poor prognostic
parameter of state of malignancy of colonic carcinoma.
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C
olorectal carcinoma (CRC) is the third-most
common malignancy (1) and is the second-most
common cause of death in the USA (2).
In Iraq, CRC is the seventh-most common type of
malignancy and is the first cause of death due to a
gastrointestinal malignancy. However, gastric carcinoma
is the second-most frequent gastrointestinal malignancy
(3). The sex incidence of CRC is about the same, though
the incidence rises sharply with age in both sexes (4).
Furthermore, many other factors have been known to
contribute significantly in the increased incidence of
CRC. These factors include geographical variation,
family history, diet, chronic inflammatory disease and
polyposis syndrome (59).
Vascular endothelial growth factor (VEGF)i sa n
important signalling protein involved in both vasculogen-
esis and angiogenesis (1013). VEGF (usually refers
to VEGF-A) gene which locates on chromosome
6p12, contains eight exons. The various VEGF-A coding
regions give seven isoforms, the most common four are:
VEGF-121, VEGF-165, VEGF-189 and VEGF-206 (12).
The VEGF protein is a heparin-binding glycoprotein with
45 kDa. VEGF belongs to the platelet-derived growth
factor (PDGF) family. There are six types of VEGF:
VEGF-A, B, C, D, E and F (12). The activity of VEGF
protein is mainly on the vascular endothelial cells (so its
name is derived from this fact) (1315). The present study
w a sd e s i g n e dt os t u d yt h eo v e r e x p r e s s i o no fVEGF in CRC
in relation to grade and stage of the tumour among a group
of Iraqi patients who referred to Kufa School of medicine
teaching hospital for histopathological evaluation.
Patients and methods
During a one-year period starting from November 2006
to November 2007, 52 patients (27 male and 25 female)
with CRC and 22 cases of non-cancerous lesion as a
control group were subjected to the present investigation.
All cases were referred to Kufa School of medicine
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Euphrates area of Iraq for histopathological evaluation.
All cases, whether malignant or non-cancerous lesions,
were examined by two histopathologists independently
and then subjected to the immunohistochemical method
using the ABC technique. The total number of malignant
cases was 52 (all were hemicolectomy or segment resec-
tion). Left side cases were 19, lower rectal tumours were
13 and right side were 20, while the total number of non-
cancerous cases was 22 (all were endoscopic biopsies).
The malignant colonic cases were staged according to the
TNM (tumor size, lymph node involvement, distant
metastasis) staging system (16). The mean age of patient
was 58.1 years. The avidinbiotin complex (ABC) method
was used for immunohistochemical detection of 0.2 mL
(Clone VG1, Code M7273, LOT 00028659, Dako Den-
mark A/S Produktionsvej 42 DK-2600 Glostrup) as
primary antibody for the detection of VEGF protein
(Kit K5204, Dako Co). The antibody sensitivity and
specificity were 98% and 100%, respectively. A Staining
kit, Code K0673, from Dako Co, was also used. The
criterion for a positive immune reaction was a dark-
brown cytoplasmic precipitate. The intensity scoring of
the staining was assessed quantitatively by counting the
percentage of positive cells in 100 malignant cells at 40
total magnifications for at least 25 fields and qualitatively
as dense and faint staining. A four-scaled scorings system
was chosen in this study; Score 0 (negative): no stained
malignant cells, Score 1 (weak): 510% of malignant cells,
Score 2 (moderate):B25% of positive malignant cells,
Score 3 (strong): 2550% of malignant cells and Score 4
(very strong):  50% of malignant cells (16).
Statistical analysis
The results were statistically evaluated with the help
of SSPS software by using Chi-square test and
CorrelationRegression test.
Results
The positive results for VEGF immunohistochemical
staining appear as brown cytoplasmic colour. Regarding
the non-cancerous colonic tissue, 4 (18.2%) out of 22
cases showed positive immunohistochemical stain for
VEGF, while 27 (51.9%) out of 52 malignant cases
showed positive results with a significant difference
between these two groups (pB0.05) (Table 1, Fig. 1).
VEGF overexpression was reported in 52% of adeno-
carcinoma and 50% of squamous cell carcinoma without
any significant difference between the two groups
(p 0.05) (Table 1, Figs. 2 and 3).
VEGF overexpression was found to be positive in
47.4% of grade I CRC, in 11 (52.4%) of grade II CRC,
and in seven (58.3%) of grade III CRC. There was good
correlation between the grade of tumour and VEGF
overexpression (r0.96, pB0.05) (Table 1).
VEGFoverexpression was found to be positive in seven
(53.8%) of stage I CRC, in 11 (52.4%) of stage II CRC
and in nine (50%) of stage III CRC. There was no
Table 1. VEGFoverexpression in relation to grade and stage
of colorectal carcinoma
Pathological
parameters
VEGF
positive
VEGF
negative Total p-Value
Non-cancerous 4 (18.2%) 18 (81.8) 22 (29.7%) B0.05
Malignant 27 (51.9%) 25 (48.1%) 52 (70.3%) R0.81
Adenocarcinoma 26 (52%) 24 (48%) 50 (96.2%)
Squamous
carcinoma
1 (50%) 1 (50%) 2 (3.8%)
Grade
Grade 1 9 (47.4%) 10 (56.6%) 19 (36.5%) B0.05
Grade 2 11 (52.4%) 10 (47.6%) 21 (40.4%) R0.96
Grade 3 7 (58.3%) 5 (41.7%) 12 (23%)
TNM stage
I 7 (53.8%) 6 (46.2%) 13 (25%)  0.05
II 11 (52.4%) 10 (47.6%) 21 (40.4%) R0.05
III 9 (50%) 9 (50%) 18 (34.6%)
Fig. 1. Normal colonic tissue with positive VEGF immu-
nostaining, score 2.
Fig. 2. Squamous cell carcinoma of rectum, grade II
exhibiting positive faint, score 1 VEGF immunostaining.
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overexpression (r0.96, pB0.05) (Table 1).
Regarding the intensity scorings of positive results of
VEGF immunohistochemical staining, score 1 was found
in 14 (51.9%) cases, score 2 in eight (19.65) cases, score 3
in four (14.8%) cases and score 4 was found only in one
case (3.7%) of CRC. There was a strong correlation of
VEGF immunohistochemical staining scoring with the
grade of CRC (Table 2).
In relation to the staining pattern (dense or faint) of
positive VEGF immunohistochemical staining, faint
staining was seen in 40.7% (11 out of 27 cases) while
the dense mode of immunostaining was reported in
59.3% (16 out of 27) (Table 2).
Discussion
Angiogenesis is crucial for tumour development. VEGF is
considered as the most important, directly acting and
potent angiogenic agent that has been shown to be over
expressed in CRC. In the present investigation, VEGF
was expressed in 18.2% of non-cancerous colonic tissue
indicating that VEGF is an effective angiogenic factor in
normal physiological conditions in the colon (1721).
However, a positive VEGF immunostaining was found
in 51.9% (27 out of 52 cases) of the study group of CRC
with a significant difference of (pB0.05) as compared
with the non-cancerous control samples. This observation
indicates that VEGF has a fundamental role in the
angiogenesis of CRC (18, 2224).
A positive correlation between the intensity of VEGF
immunostaining and histological types of CRC has been
noted, with a significant difference among these three
subtypes in relation to the VEGF over expression. This
finding is in complete agreement with that reported
elsewhere (25).
There was a positive correlation between the VEGF
immunostaining and the pattern of staining (dense or
faint) (r0.92, pB0.05) suggesting that colonic cancer is
a highly vascular malignancy and the malignant colonic
cancer cells are highly susceptible to the action of VEGF.
As grouped in Table 1, the present study shows that
there was a gradual increase in the frequency of VEGF
expression in parallel with the increase in the grade of
tumour (in grade I there was 50% VEGF expression, in
grade II 52% and in grade III 54.5%). However, no
significant differences among the three degrees of differ-
entiation (p 0.05) were noted. This observation is
supported by previous investigators who reached the
same conclusion (26, 27). Furthermore, there was a
significant correlation between the stage of tumour
and the intensity of VEGF immunostaining (pB0.05,
Fig. 3. Adenocarcinoma of colon, grade I, stage II with
positive dense VEGF immunostaining, score 4 (10).
Table 2. Intensity of vascular endothelial growth factors in relation to grade, stage and pattern of immunostaining in colorectal
carcinoma
Intensity of stain Score 0 Score 1 Score 2 Score 3 Score 4 Total
Grade
I 10 (50%) 3 (15%) 2 (1%) 4 (20%) 1 (0.5%) 20 (38.46%)
II 10 (47.6%) 6 (28.6%) 5 (23.81%) 0 (0%) 0 (0%) 21 (40.4%)
III 5 (45.6%) 4 (36.4%) 2 (18%) 0 (0%) 0 (0%) 11 (21.15%)
pB0.05 R0.96
Stage
I 6 (42.9%) 5 (35.7%) 2 (14.3%) 1 (7.1%) 0 (0%) 14 (26.9%)
II 10 (47.6%) 4 (19%) 3 (14.1%) 3 (14.1%) 1 (4.2%) 21 (40.4%)
III 9 (50%) 5 (2.7%) 3 (15.8%) 1 (5.6%) 0 (0%) 17 (32.7%)
pB0.05 R0.62
Pattern
Faint 0 (0%) 8 (72.7%) 2 (18.2%) 1 (9%) 0 (0%) 11 (40.7%)
Dense 0 (0%) 6 (36.5%) 6 (36.5%) 3 (18.8%) 1 (6.3%) 16 (59.3%)
pB0.05 R0.95
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directly proportional to the degree of colorectal tumour
spread as has been established elsewhere (18, 2730).
There is no significant difference among the three stages
of CRC in relation to VEGF expression (p 0.05).
Conclusion
These findings unfold further evidence for the role of
VEGF in the carcinogenesis of CRC. Accordingly, VEGF
could be considered as a poor prognostic parameter of
colonic carcinoma.
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